Investigational drug · Phase 3
KP-100LI
Also called: Hepatocyte Growth Factor, HGF
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Vocal Fold Scar.
Phase 3Last checked: Nov 20, 2026Latest source record: Jul 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "KP-100LI"
First trial start
2022
Dec 1, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "KP-100LI", any sponsor or status.
Conditions studied
As listed on its trial records.
- Vocal Fold Scar
Largest trials
Live from ClinicalTrials.gov: studies naming "KP-100LI" as an intervention, largest first.
- Phase 3 Study of KP-100LI in Subjects With Vocal Fold ScarPivotal-lookingActive, not recruiting
Kringle Pharma, Inc.Industry
NCT05627648 · 62 participants (planned) · Start Dec 1, 2022 · Primary completion Jul 31, 2026
Drug: KP-100LI; Placebo · For: Vocal Fold Scar
Sites: Toyoake, Japan; Fukuoka, Japan; Kurume, Japan · 8 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Iron-quercetin-incorporated PCL/PEO nanofibrous scaffolds for ADSC secretome modulation and in vitro regenerative responses.
Daranarong D, Kantapan J, Jenvoraphot T, et al. · Biomater Adv 2027
- Xiaoqinglong decoction suppresses M1 macrophage polarization in COPD via the MET/AKT/HK2 axis: An integrated multi-omics analysis.
Zhang F, Gu J, Li Y, et al. · J Ethnopharmacol 2027
- Regulation of epithelial-mesenchymal cell-cell partners by complexes of paracrine signals and sulfated oligosaccharides.
Zhang W, Wauthier E, Xu Y, et al. · Biomaterials 2027
- Melatonin modulates granulosa cell angiogenesis differently in female- and male-factor infertility.
Cavalcanti GS, Carvalho KC, Monteleone PAA, et al. · Gynecol Endocrinol 2026
- Co-conditioning and parallel cell homing-driven pre-metastatic niche engineering: TGF-β-fuelled 3D microphysiological model for epithelial-mesenchymal transition in breast cancer.
Vaishnavi M, Kumari M, Pal S, et al. · In Vitro Model 2026
- Exosomes from induced and adipose-derived MSCs regulate NRK-52E cells under hyperglycemic conditions.
Ababneh NA, Aldiqs R, Ismail MA, et al. · Res Pharm Sci 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.